LISA MOSTOVOY
LISA MOSTOVOY, Senior VP, Next Gen Commercialization, Population Health Partners
Lisa Mostovoy, PharmD, MBA is the SVP, Next Gen Commercialization, at Population Health Partners (PHP). Prior to joining PHP, Lisa led Payer Partnership at EQRx. Lisa’s team was responsible for building meaningful, long-term, strategic partnerships with US payers and developing innovative commercial contracts. Prior to EQRx, Lisa served in a number of leadership positions at Blue Cross Blue Shield Association (BCBSA) and was responsible for pharmacy strategy and innovation across the Blues. Prior to BCBSA, Lisa managed national employer groups at CVS Health focusing on overall clinical strategy, management of complex custom formularies, utilization management, and benefit design.
Lisa completed a managed care residency with CVS Health, holds a Bachelor of Biology from Stevenson University, Doctor of Pharmacy from University of Maryland, and Master of Business Administration from University of Baltimore. Throughout Lisa’s professional career, her passion has been and remains - lowering the cost of and making life-saving therapies accessible for all.
19th September 8th Pharma Pricing, Reimbursement & Market Access 2024 – Day 1
14:30 – Payer and Other Stakeholder Prospectives – An Actuarial View
• Understand how Part D and commercial payers value formulary financial decisions while balancing clinical considerations
• Describe the financial liability and risk differentiation between PBMs, GPOs, and payers
• Learn how Part D and commercial payers examine selection and utilization risk in determining formulary access
• Review a case study on how drug manufacturers establish pricing that aligns with payer net liability concerns
STEPHEN GEORGE, Senior Consultant, Milliman
PAMELA LABOY, Consulting Actuary, Milliman
19th September 8th Pharma Pricing, Reimbursement & Market Access 2024 – Day 1
15:00 – Afternoon Tea / Coffee & Networking
19th September 8th Pharma Pricing, Reimbursement & Market Access 2024 – Day 1
15:30 – WAC Marketing: The Potential for Price Messaging in the Pharmaceutical Industry
• Several case studies indicate a need for framing pricing with clear and transparent communication
• Recent examples demonstrate a variety of strategies in price-focused messaging
• There are both benefits and challenges of proactive and/or reactive approaches
• Some considerations: potential obstacles and limitations to price-focused messaging
ERIC BACHMAN, Founder, Invisible Economics
19th September 8th Pharma Pricing, Reimbursement & Market Access 2024 – Day 1
DIGITAL ACCESSIBILITY
16:00 – What does Digital Accessibility Mean for Pharma
With the Americans with Disability Act (ADA) in place for nearly 34 years (July 26, 1990), the awareness and practice of digital accessibility has experienced a remarkable crescendo in recent years – becoming a central tenant of Diversity Equity & Inclusion (DE&I), Environmental Social & Governance (ESG), and the Social Determinants of Health (SDOH). With the rising tide of global legislation (the nice-to-have becoming the must-have), explore the potential implications to clinical trial drug development, manufacturing, and commercial for the inclusive patient and consumer experience.
STEPHEN FRAMIL, Corporate Global Head of Accessibility, Merck
19th September 8th Pharma Pricing, Reimbursement & Market Access 2024 – Day 1
16:40 – Chairperson’s closing remarks and end of conference day 01
19th September 8th Pharma Pricing, Reimbursement & Market Access 2024 – Day 1
16:50 – 18:00 – Networking Drinks